Emergent (EBS) Reports Q4 2025 Earnings with Strong Financial Performance
Emergent (EBS) reported strong Q4 2025 earnings, with adjusted EBITDA increasing by 12% year-over-year to $205 million and gross margin improving by 900 basis points for the full year. The company also saw a significant reduction in operating expenses and improved net leverage, indicating strong financial health.
Tickers: $EBS
Topics: buyback earnings FDA approval financial results operational efficiency profitability revenue